B. Braun settles with the DOJ over contaminated syringes

B. Braun Medical has agreed to pay almost $8 million in penalties, forfeiture and restitution to resolve its criminal liability related to the sale of contaminated prefilled saline flush syringes that dates back to 2007. The syringes were manufactured by another company, but sold under the B. Braun label. "The Federal Food, Drug and Cosmetic Act (FDCA) prohibits companies from selling contaminated products, even when the company did not make the product itself," said Principal Deputy Assistant Attorney General Benjamin Mizer, head of the Justice Department's Civil Division, in a statement. "Companies must take reasonable steps to ensure that their suppliers are making quality products that help rather than harm patients. Today's settlement shows that the government will continue to hold companies accountable for failing to fulfill this critically important responsibility." More

Suggested Articles

Millions of tests are urgently needed as the virus keeps communities across the country in lockdown and hospitals are overwhelmed with patients.

The FDA granted its first emergency authorization for a rapid antibody blood test for COVID-19 developed by Cellex.

The ultimate goal is to move as many patients as possible out of the clinic that don’t need immediate, critical care.